Federated Hermes Inc. Acquires 685,906 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Federated Hermes Inc. grew its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 36,542.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 687,783 shares of the company's stock after buying an additional 685,906 shares during the quarter. Federated Hermes Inc. owned 0.44% of Xeris Biopharma worth $3,776,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in XERS. NewEdge Advisors LLC bought a new position in Xeris Biopharma during the 4th quarter valued at about $34,000. Apella Capital LLC bought a new position in Xeris Biopharma during the first quarter valued at approximately $55,000. Xponance Inc. purchased a new stake in Xeris Biopharma in the first quarter worth approximately $57,000. FNY Investment Advisers LLC bought a new stake in Xeris Biopharma in the 1st quarter worth approximately $63,000. Finally, Raymond James Financial Inc. purchased a new stake in Xeris Biopharma during the 4th quarter valued at $45,000. Institutional investors own 42.75% of the company's stock.

Wall Street Analysts Forecast Growth

XERS has been the subject of several research analyst reports. Wall Street Zen lowered Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer raised their target price on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $6.25.

Xeris Biopharma Trading Up 1.4%

Xeris Biopharma stock traded up $0.10 during trading on Friday, reaching $6.70. The company had a trading volume of 8,928,401 shares, compared to its average volume of 2,531,544. The firm's 50-day simple moving average is $4.92 and its 200 day simple moving average is $4.55. Xeris Biopharma Holdings, Inc. has a 52 week low of $2.21 and a 52 week high of $7.09. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -22.28 and a beta of 0.65.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million. On average, analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Insider Activity

In other news, insider Kevin Mcculloch bought 25,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The stock was bought at an average price of $4.38 per share, with a total value of $109,500.00. Following the acquisition, the insider owned 1,708,585 shares of the company's stock, valued at approximately $7,483,602.30. This represents a 1.48% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.47% of the stock is currently owned by company insiders.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.